Further Evidence That OPG rs2073618 Is Associated With Increased Risk of Musculoskeletal Symptoms in Patients Receiving Aromatase Inhibitors for Early Breast Cancer
ConclusionCarriers of OPG rs2073618 may be at increased risk of AIMSS. If confirmed in other cohorts, OPG genotyping can be used to identify individuals with HR + early breast cancer in whom alternate endocrine therapy or interventions to enhance symptom detection and implement strategies to reduce musculoskeletal symptoms may be needed. (Source: Frontiers in Genetics)
Source: Frontiers in Genetics - June 15, 2021 Category: Genetics & Stem Cells Source Type: research
Interaction between SNP Genotype and Efficacy of Anastrozole and Exemestane in Early Stage Breast Cancer
Clin Pharmacol Ther. 2021 May 28. doi: 10.1002/cpt.2311. Online ahead of print.ABSTRACTAromatase inhibitors (AI) are the treatment of choice for hormone receptor-positive early breast cancer in postmenopausal women. None of the third-generation AIs are superior to the others in terms of efficacy. We attempted to identify genetic factors that could differentiate between the effectiveness of adjuvant anastrozole and exemestane by examining single-nucleotide polymorphism (SNP)-treatment interaction in 4465 patients. A group of SNPs were found to be differentially associated between anastrozole and exemestane regarding outcome...
Source: Clinical Breast Cancer - May 28, 2021 Category: Cancer & Oncology Authors: Junmei Cairns Krishna R Kalari James N Ingle Lois E Shepherd Matthew J Ellis Paul E Goss Poulami Barman Erin E Carlson Barbara Goodnature Matthew P Goetz Richard M Weinshilboum Huanyao Gao Liewei Wang Source Type: research
Interaction between SNP Genotype and Efficacy of Anastrozole and Exemestane in Early Stage Breast Cancer
Clin Pharmacol Ther. 2021 May 28. doi: 10.1002/cpt.2311. Online ahead of print.ABSTRACTAromatase inhibitors (AI) are the treatment of choice for hormone receptor-positive early breast cancer in postmenopausal women. None of the third-generation AIs are superior to the others in terms of efficacy. We attempted to identify genetic factors that could differentiate between the effectiveness of adjuvant anastrozole and exemestane by examining single-nucleotide polymorphism (SNP)-treatment interaction in 4465 patients. A group of SNPs were found to be differentially associated between anastrozole and exemestane regarding outcome...
Source: Clinical Genitourinary Cancer - May 28, 2021 Category: Cancer & Oncology Authors: Junmei Cairns Krishna R Kalari James N Ingle Lois E Shepherd Matthew J Ellis Paul E Goss Poulami Barman Erin E Carlson Barbara Goodnature Matthew P Goetz Richard M Weinshilboum Huanyao Gao Liewei Wang Source Type: research
Interaction between SNP Genotype and Efficacy of Anastrozole and Exemestane in Early Stage Breast Cancer
Clin Pharmacol Ther. 2021 May 28. doi: 10.1002/cpt.2311. Online ahead of print.ABSTRACTAromatase inhibitors (AI) are the treatment of choice for hormone receptor-positive early breast cancer in postmenopausal women. None of the third-generation AIs are superior to the others in terms of efficacy. We attempted to identify genetic factors that could differentiate between the effectiveness of adjuvant anastrozole and exemestane by examining single-nucleotide polymorphism (SNP)-treatment interaction in 4465 patients. A group of SNPs were found to be differentially associated between anastrozole and exemestane regarding outcome...
Source: Clinical Pharmacology and Therapeutics - May 28, 2021 Category: Drugs & Pharmacology Authors: Junmei Cairns Krishna R Kalari James N Ingle Lois E Shepherd Matthew J Ellis Paul E Goss Poulami Barman Erin E Carlson Barbara Goodnature Matthew P Goetz Richard M Weinshilboum Huanyao Gao Liewei Wang Source Type: research
Interaction between SNP Genotype and Efficacy of Anastrozole and Exemestane in Early Stage Breast Cancer
Clin Pharmacol Ther. 2021 May 28. doi: 10.1002/cpt.2311. Online ahead of print.ABSTRACTAromatase inhibitors (AI) are the treatment of choice for hormone receptor-positive early breast cancer in postmenopausal women. None of the third-generation AIs are superior to the others in terms of efficacy. We attempted to identify genetic factors that could differentiate between the effectiveness of adjuvant anastrozole and exemestane by examining single-nucleotide polymorphism (SNP)-treatment interaction in 4465 patients. A group of SNPs were found to be differentially associated between anastrozole and exemestane regarding outcome...
Source: Clinical Breast Cancer - May 28, 2021 Category: Cancer & Oncology Authors: Junmei Cairns Krishna R Kalari James N Ingle Lois E Shepherd Matthew J Ellis Paul E Goss Poulami Barman Erin E Carlson Barbara Goodnature Matthew P Goetz Richard M Weinshilboum Huanyao Gao Liewei Wang Source Type: research
Interaction between SNP Genotype and Efficacy of Anastrozole and Exemestane in Early Stage Breast Cancer
Clin Pharmacol Ther. 2021 May 28. doi: 10.1002/cpt.2311. Online ahead of print.ABSTRACTAromatase inhibitors (AI) are the treatment of choice for hormone receptor-positive early breast cancer in postmenopausal women. None of the third-generation AIs are superior to the others in terms of efficacy. We attempted to identify genetic factors that could differentiate between the effectiveness of adjuvant anastrozole and exemestane by examining single-nucleotide polymorphism (SNP)-treatment interaction in 4465 patients. A group of SNPs were found to be differentially associated between anastrozole and exemestane regarding outcome...
Source: Clinical Genitourinary Cancer - May 28, 2021 Category: Cancer & Oncology Authors: Junmei Cairns Krishna R Kalari James N Ingle Lois E Shepherd Matthew J Ellis Paul E Goss Poulami Barman Erin E Carlson Barbara Goodnature Matthew P Goetz Richard M Weinshilboum Huanyao Gao Liewei Wang Source Type: research
Interaction between SNP Genotype and Efficacy of Anastrozole and Exemestane in Early Stage Breast Cancer
Clin Pharmacol Ther. 2021 May 28. doi: 10.1002/cpt.2311. Online ahead of print.ABSTRACTAromatase inhibitors (AI) are the treatment of choice for hormone receptor-positive early breast cancer in postmenopausal women. None of the third-generation AIs are superior to the others in terms of efficacy. We attempted to identify genetic factors that could differentiate between the effectiveness of adjuvant anastrozole and exemestane by examining single-nucleotide polymorphism (SNP)-treatment interaction in 4465 patients. A group of SNPs were found to be differentially associated between anastrozole and exemestane regarding outcome...
Source: Clinical Pharmacology and Therapeutics - May 28, 2021 Category: Drugs & Pharmacology Authors: Junmei Cairns Krishna R Kalari James N Ingle Lois E Shepherd Matthew J Ellis Paul E Goss Poulami Barman Erin E Carlson Barbara Goodnature Matthew P Goetz Richard M Weinshilboum Huanyao Gao Liewei Wang Source Type: research
Anastrozole and levonorgrestrel-releasing intrauterine device in the treatment of endometriosis: a randomized clinical trial
To study the effectiveness of an aromatase inhibitor (Anastrozole) associated with levonorgestrel-releasing intrauterine device (LNG-IUD, Mirena ®) in the treatment of endometriosis. (Source: BMC Women's Health)
Source: BMC Women's Health - May 20, 2021 Category: OBGYN Authors: Pedro Aci én, Irene Velasco and Maribel Acién Tags: Research article Source Type: research
Delayed hypersensitivity reactions to multiple aromatase inhibitors followed by successful desensitization to letrozole
Aromatase inhibitors (AIs) are a class of medications that can suppress plasma estrogen levels by inhibiting or inactivating aromatase –the enzyme responsible for converting androgens to estrogens.1 They are the preferred adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive breast cancer.2 Anastrozole, letrozole and exemestane are the commonly used third-generation AIs with similar efficacy and toler ability.1,2 If patients develop intolerable side effects with one AI, they can switch to a different one. (Source: Annals of Allergy, Asthma and Immunology)
Source: Annals of Allergy, Asthma and Immunology - May 15, 2021 Category: Allergy & Immunology Authors: Erika Yue Lee, Orit Freedman, Mariana Castells, Peter Vadas Source Type: research
Efficacy and safety of endocrine therapy for breast-cancer prevention in high-risk premenopausal or postmenopausal women: a Bayesian network meta-analysis of nine randomized controlled trials
Conclusions and Relevance:
To sum up, ET decreased the risks of TBC, IBC, ER + BC, and ductal carcinoma in situ, while increasing the risks of pulmonary embolism, total venous thrombosis, and EC in high-risk pre- or postmenopausal women. Meanwhile, anastrozole, exemestane, and tamoxifen possibly exerted potential protective effects on TBC, IBC and ER + BC. Typically, raloxifene might be effective on IBC, while tamoxifen might increase the risk of EC. Therefore, clinicians should fully weigh the benefits and risks of ET to develop a rational individualized treatment. (Source: Menopause)
Source: Menopause - April 30, 2021 Category: OBGYN Tags: Review Article Source Type: research
Clinical outcomes in 21-hydroxylase deficiency
Purpose of review
The introduction of synthetic glucocorticoids 70 years ago made survival possible in classic 21-hydroxylase deficiency (21OHD). The currently used glucocorticoid therapy may lead to unphysiological dosing with negative consequencies on health in addition to the problems that may arise due to androgen over-exposure.
Recent findings
Fertility in females with 21OHD seemed to be impaired, especially in the salt-wasting (SW) phenotype but when pregnancies did occur there was a higher risk for gestational diabetes and cesearean section. Increased fat mass, body mass index, insulin resistance and fr...
Source: Current Opinion in Endocrinology, Diabetes and Obesity - April 30, 2021 Category: Endocrinology Tags: ADRENAL CORTEX AND MEDULLA: Edited by Irina Bancos and Diane Donegan Source Type: research
Dual treatment of acromegaly and hormone-receptor-positive breast cancer with tamoxifen: a case report
ConclusionThis case highlights the dual benefit of tamoxifen therapy in the treatment of hormone-receptor-positive breast cancer and acromegaly. Unlike anastrozole, tamoxifen has the benefit of lowering insulin-like growth factor 1 levels, which underscores its advantage in reducing adverse musculoskeletal symptoms during the treatment of hormone-receptor-positive breast cancer. We offer the first reported use of tamoxifen monotherapy for the successful treatment of acromegaly and hormone-receptor-positive breast cancer. While tamoxifen may offer an additional, oral option for acromegaly patients who do not respond to or t...
Source: Journal of Medical Case Reports - April 29, 2021 Category: General Medicine Source Type: research
First clinical experience with CDK4/6 inhibitors in breast cancer therapy
Exp Ther Med. 2021 May;21(5):522. doi: 10.3892/etm.2021.9954. Epub 2021 Mar 22.ABSTRACTFor hormone receptor-positive, HER2-negative breast cancer patients with metastatic or advanced disease, therapy with CDK4/6 inhibitors in addition to aromatase inhibitors (AIs) or to the estrogen receptor (ER) downregulator fulvestrant has resulted in an additional therapy option and a longer progression-free survival. In the Gynecologic-Oncology Clinic, Diakonie-Klinikum Schwäbisch Hall, we followed and registered our initial clinical experience with CDK4/6 inhibitors, following the side effects and tumor response over two years since...
Source: Experimental and Therapeutic Medicine - April 5, 2021 Category: General Medicine Authors: Ionut Marcel Cobec Lavinia Moleriu Aurica Elisabeta Moatar Andreas Rempen Source Type: research
Preventing Breast Cancer Through Identification and Pharmacologic Management of High-Risk Patients
Mayo Clin Proc. 2021 Apr;96(4):1033-1040. doi: 10.1016/j.mayocp.2021.01.028.ABSTRACTBreast cancer remains the most common cancer in women in the United States. For certain women at high risk for breast cancer, endocrine therapy (ET) can greatly decrease the risk. Tools such as the Breast Cancer Risk Assessment Tool (or Gail Model) and the International Breast Cancer Intervention Study risk calculator are available to help identify women at increased risk for breast cancer. Physician awareness of family history, reproductive and lifestyle factors, dense breast tissue, and history of benign proliferative breast disease are i...
Source: Clinical Breast Cancer - April 5, 2021 Category: Cancer & Oncology Authors: Elizabeth A Gilman Sandhya Pruthi Erin W Hofstatter Dawn M Mussallem Source Type: research
Preventing Breast Cancer Through Identification and Pharmacologic Management of High-Risk Patients
Mayo Clin Proc. 2021 Apr;96(4):1033-1040. doi: 10.1016/j.mayocp.2021.01.028.ABSTRACTBreast cancer remains the most common cancer in women in the United States. For certain women at high risk for breast cancer, endocrine therapy (ET) can greatly decrease the risk. Tools such as the Breast Cancer Risk Assessment Tool (or Gail Model) and the International Breast Cancer Intervention Study risk calculator are available to help identify women at increased risk for breast cancer. Physician awareness of family history, reproductive and lifestyle factors, dense breast tissue, and history of benign proliferative breast disease are i...
Source: Clinical Genitourinary Cancer - April 5, 2021 Category: Cancer & Oncology Authors: Elizabeth A Gilman Sandhya Pruthi Erin W Hofstatter Dawn M Mussallem Source Type: research
